

Lixisenatide acetate

Cat. No.:	HY-P0119A		
CAS No.:	1997361-87-1		
Molecular Formula:	$C_{215}H_{347}N_{61}O_{65}S_6C_2H_4O_2$		
Molecular Weight:	5218.79		
Sequence Shortening:	HGEGTFTSDLKQMEEEEAVRLFIEWLKNGGPSSGAPPSKSKKKKK-NH2		
Target:	Glucagon Receptor		
Pathway:	GPCR/G Protein		
Storage:	Powder	-80°C	2 years
		-20°C	1 year
	In solvent	-80°C	6 months
		-20°C	1 month

BIOLOGICAL ACTIVITY

Description	Lixisenatide acetate is a glucagon-like peptide-1 (GLP-1) receptor agonist that can be used in the treatment of type 2 diabetes mellitus (T2DM).
IC ₅₀ & Target	GLP-1 receptor ^{[1][2]} .

CUSTOMER VALIDATION

- J Mol Neurosci. 2020 Feb 10.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Ahrén B et al. Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus: A Post Hoc Analysis. *Diabetes Ther.* 2016 Jun 18.

[2]. Lorenz M, et al. Effects of lixisenatide once daily on gastric emptying in type 2 diabetes--relationship to postprandial glycemia. *Regul Pept.* 2013 Aug 10;185:1-8.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA